

**REMARKS/ARGUMENTS**

Applicants elect without traverse to prosecute the claims Group I (claims 5-16 and 24-26) in the present application. In response to the species election, applicants elect as follows:

- 1) A dipeptidyl peptidase IV inhibitor which is 3-(2-butynyl)-5-methyl-2-(piperazin-1-yl)-3,5-dihydroimidazo[4,5-d]pyridazin-4-one (compound 2 in claim 16);
- 2) A biguanide which is metformin; and
- 3) A disease which is diabetes.

Claims 5-9, 11-16 and 24-26 read on the elected species. Applicants respectfully remind the Examiner that upon the allowance of a generic claim applicant is entitled to consideration of additional species within the scope of the allowed claims.

Claims 29 and 33 are withdrawn from examination as being drawn to a non-elected invention. However, the elected claims and claims 29 and 33 are related as composition and methods of using the compositions. Pursuant to M.P.E.P. § 821.04, Applicants reserve the right to rejoinder of method claims so long their scope corresponds to that of the composition claims..

**CONCLUSION**

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at 415-576-0200.

Respectfully submitted,

/Kevin Bastian/

Kevin Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
Attachments

KLB:klb  
61268042 v1  
a